Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.
Based in Rahway, Merck (MRK) is in the Medical sector, and so far this year, shares have seen a price change of -11.86%. The pharmaceutical company is paying out a dividend of $0.81 per share at the ...
If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...
Merck Foundation Chief Executive Officer (CEO) advanced Cancer Care in Africa by providing 194 Oncology Scholarships in ...
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
DUBLIN (Reuters) - Ireland's foreign direct investment agency is hopeful that the impact of threatened U.S. tariffs on the country's large pharmaceutical sector will be limited by a U.S. desire to ...
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.
Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases ---- Amit Munshi ...
Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...
Investor's Business Daily on MSN3d
Is Moderna Stock A Buy As Its CEO Fends Off RFK Jr. Concerns?Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback